Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group.
about
Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department.Atrial tachyarrhythmia in adult congenital heart diseaseTreating critical supraventricular and ventricular arrhythmias.Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillationEmergency management of atrial fibrillationIbutilide for treatment of atrial fibrillation in the emergency departmentAnti-Arrhythmic Agents in the Treatment of Atrial Fibrillation.Executive Summary: European Heart Rhythm Association Consensus Document on the Management of Supraventricular Arrhythmias: Endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de EstimulacióIncreasing gap junction coupling suppresses ibutilide-induced torsades de pointes.Pretreatment with intravenous amiodarone improves the efficacy of ibutilide treatment on cardioversion rate and maintenance time of sinus rhythm in patients with persistent atrial fibrillation.Pediatric Dosing of Intravenous Sotalol Based on Body Surface Area in Patients with ArrhythmiaIntravenous Sotalol - Reintroducing a Forgotten Agent to the Electrophysiology Therapeutic Arsenal.Loss of Side-to-Side Connections Affects the Relative Contributions of the Sodium and Calcium Current to Transverse Propagation Between Strands of Atrial Myocytes
P2860
Q33589789-8709AACB-A504-411A-9C26-0372233B3E72Q33854123-7083229D-1226-4719-AF5A-47BE4E5652CFQ33909242-7061A6D1-97A4-4518-B8B1-718B7CF63E35Q34523170-89BD160B-F64B-424B-9EC5-BAA4E3122812Q35168643-C3BB544E-4D5C-447E-8732-A3CB4439E7F1Q36929148-9A9C3501-43CA-44A2-915D-A1A13330E63DQ37495803-CE63A9F6-DCE0-4384-971D-03EE1630F62AQ37596058-BE8A91B3-30CB-4FD1-9DEF-2162AFB5D22EQ37710038-BC272F17-B823-4CE2-B9C6-8FE8F7A9DA3BQ42051574-45B904F1-FF56-4355-8089-52FD56D5A409Q42370388-4C343E82-B7E3-46E5-9A9E-56555C795342Q47140393-31EF6233-52E4-4F72-A8F4-CD40859899CCQ58764728-3B294957-659C-48CC-8EA1-ED001B1EAE7B
P2860
Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Superiority of ibutilide (a ne ...... otalol Comparator Study Group.
@ast
Superiority of ibutilide (a ne ...... otalol Comparator Study Group.
@en
type
label
Superiority of ibutilide (a ne ...... otalol Comparator Study Group.
@ast
Superiority of ibutilide (a ne ...... otalol Comparator Study Group.
@en
prefLabel
Superiority of ibutilide (a ne ...... otalol Comparator Study Group.
@ast
Superiority of ibutilide (a ne ...... otalol Comparator Study Group.
@en
P2093
P2860
P1433
P1476
Superiority of ibutilide (a ne ...... otalol Comparator Study Group.
@en
P2093
Golitsyn SR
Steinbeck G
Van Wijk LV
Wellens HJ
P2860
P304
P407
P577
1998-06-01T00:00:00Z